NCCN Flash Updates: NCCN Templates® Updated for Head and Neck Cancers
NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Head and Neck Cancers to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Head and Neck Cancers v1.2021.
- The following NCCN templates have been DELETED and combined with other existing templates:
- HDN6: CISplatin with Concurrent Radiation (content on HDN1)
- HDN49: Cetuximab with Concurrent Radiation (content on HDN26)
- The following NEW NCCN templates have been published:
- HDN44: PACLitaxel/CARBOplatin with Concurrent Radiation
- HDN51: PACLitaxel/CISplatin/Fluorouracil Followed by Chemoradiation
- HDN54: CISplatin or CARBOplatin and Concurrent Radiation followed by Adjuvant Chemotherapy- CARBOplatin/Fluorouracil course
- HDN55: DOCEtaxel/CISplatin/Fluorouracil Followed by Chemoradiation
- HDN56: CISplatin/Fluorouracil Followed by Chemoradiation
- HDN57: EpiRUBicin/PACLitaxel/CISplatin Followed by Chemoradiation
- HDN58: Weekly CISplatin with Concurrent Radiation
- HDN59: CARBOplatin with Concurrent Radiation
- HDN65: DOCEtaxel/CISplatin Followed by Chemoradiation
- HDN95: Gemcitabine/CISplatin followed by Chemoradiation
- HDN102: CARBOplatin with Concurrent Radiation followed by Adjuvant Chemotherapy- CARBOplatin with Concurrent Radiation
- Changes to the Indications and Chemotherapy Regimen sections have been made to the following templates:
- HDN1: High-dose CISplatin with Concurrent Radiation
- HDN16: CISplatin + Cetuximab
- HDN17: CISplatin
- HDN18: CARBOplatin
- HDN19: PACLitaxel
- HDN20: DOCEtaxel
- HDN22: Methotrexate
- HDN26: Cetuximab with Concurrent Radiation
- HDN36: DOCEtaxel/CARBOplatin
- HDN37: Cetuximab
- HDN48: Weekly CISplatin with Concurrent Radiation
- HDN50: CISplatin/Fluorouracil
- Changes to the Indications have been made to the following templates:
- HDN7: PACLitaxel/CARBOplatin
- HDN21: Fluorouracil
- HDN34: DOCEtaxel/CISplatin
- HDN35: PACLitaxel/CISplatin
- References have been updated on the following templates:
- HDN1: High-dose CISplatin with Concurrent Radiation
- HDN5: CARBOplatin/Fluorouracil with Concurrent Radiation
- HDN7: PACLitaxel/CARBOplatin
- HDN8: DOCEtaxel/CISplatin/Fluorouracil Followed by Chemoradiation
- HDN48: Weekly CISplatin with Concurrent Radiation
- Changes to the Emetic risk have been made to the following templates:
- HDN3: PACLitaxel/CISplatin
- Changes to the Chemotherapy Regimen section have been made to the following templates:
- HDN3: PACLitaxel/CISplatin
- HDN5: CARBOplatin/Fluorouracil with Concurrent Radiation
- HDN8: DOCEtaxel/CISplatin/Fluorouracil Followed by Chemoradiation
- HDN9: CISplatin with Concurrent Radiation followed by Adjuvant Chemotherapy- CISplatin with Concurrent Radiation
- HDN10: CISplatin with Concurrent Radiation followed by Adjuvant Chemotherapy- CISplatin/Fluorouracil
- HDN45: CARBOplatin with Concurrent Radiation
- The following myeloid growth factor note for templates with a febrile neutropenia risk of “high” has been revised in the Supportive Care section
- Filgrastim (or clinically appropriate G-CSF agent) 5 mcg/kg subcutaneously daily, recommended to start the day following or up to 3 – 4 days after completion of chemotherapy and to continue until post-nadir ANC recovery to normal or near-normal levels by laboratory standards. Dose is rounded to the nearest vial size by institution-defined weight limits. Same-day administration is not recommended.
OR
Pegfilgrastim (or clinically appropriate biosimilar) 6 mg subcutaneously once, recommended to be given the day following or up to 3 – 4 days after completion of chemotherapy. There are insufficient data to support use of pegfilgrastim for cytotoxic chemotherapy regimens administered less frequently than every 2 weeks. Same-day administration is not recommended.
- For more information on prophylaxis of febrile neutropenia and a list of appropriate agents, refer to the Myeloid Growth Factors algorithms in the NCCN Guidelines for Hematopoietic Growth Factors and Appendix C to the NCCN Templates.
- Affected templates
- HDN8: DOCEtaxel/CISplatin/Fluorouracil Followed by Chemoradiation
- Drug information notes for the following medications have been updated in the Supportive Care, Monitoring and Hold Parameters, and/or Safety Parameters and Special Instructions sections:
- CARBOplatin
- Cetuximab
- CISplatin
- DOCEtaxel
- Fluorouracil
- Hydroxyurea
- Methotrexate
- PACLitaxel
NCCN has published updates to the following NCCN Guidelines with NCCN Evidence Blocks™:
- Head and Neck Cancers, Version 1.2021
For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.
To view the NCCN Guidelines for Patients®, please visit NCCN.org/patientguidelines.
Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.
About NCCN Flash Updates™
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content.
Subscribe to NCCN Flash Updates™
Please note: The NCCN Third Party Content FTP site: ftp://ftp1.nccn.org/ThirdPartyContent/ has been updated. Licensees are solely responsible for obtaining permission from such third party to use any such Third Party Content in the Permitted Works.
Access information on permissions and licensing of NCCN Content
Users may unsubscribe from Flash Updates at any time contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.